Robert J. Priar - Jun 1, 2021 Form 4 Insider Report for Bionano Genomics, Inc (BNGO)

Role: Chief Commercial Officer
Signature: /s/ R. Erik Holmlin, Attorney-in-Fact
Stock symbol: BNGO
Transactions as of: Jun 1, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/8/2021, 05:03 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BNGO	Stock Option (Right to Buy)	Award	$0	+400K		$0.00	400K	Jun 1, 2021	Common Stock	400K	$6.32	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the option shall vest and become exercisable on June 1, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 1, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan.

Content

25% of the shares subject to the option shall vest and become exercisable on June 1, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 1, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan.